Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Osteoporosis
Published in: Archives of Osteoporosis 1/2019

01-12-2019 | Bisphosphonate | Original Article

Oral bisphosphonate use and the risk of female breast, ovarian, and cervical cancer: a nationwide population-based cohort study

Authors: Ye Seul Bae, Jooyoung Chang, Sang Min Park

Published in: Archives of Osteoporosis | Issue 1/2019

Login to get access

Abstract

Summary

Bisphosphonate use was not associated with the risk of female breast, ovarian, or cervical cancer. The results according to bisphosphonate type or concurrent drug uses were not associated with the cancer risk. The protective effect of bisphosphonate use on female breast cancer was significant in the low comorbidity group.

Purpose

Despite the antitumor mechanisms, the effect of bisphosphonates on the risk of cancer is still unclear. We investigated the association between oral bisphosphonate use and the development of female breast, ovarian, and cervical cancer.

Methods

We accomplished a population-based cohort study using the National Health Insurance Services (NHIS) database. A total of 204,525 participants were included in a cohort, and we identified the incident cases of each cancer from 2007 to 2013. We assessed cumulative bisphosphonate exposure from 2003 to 2006 using the defined daily dose (DDD) system. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were presented to assess the association between bisphosphonate use and cancer incidence using multivariate Cox proportional hazard regression models. Subgroup analyses were performed to assess cancer development according to risk factors and concurrent drug use.

Results

There was a total of 1547, 266, and 370 incident cases of female breast, cervical, and ovarian cancer, respectively, during the study period of 1,367,294 person-years. Bisphosphonate exposure was not significantly associated with risk of female breast (adjusted HR (aHR), 0.78; 95% CI, 0.60–1.02), ovarian (aHR, 1.30; 95% CI, 0.82–2.07), nor cervical cancer (aHR, 0.70; 95% CI, 0.44–1.12). Further subgroup analyses also revealed no statistically significant effects of bisphosphonate use with various risk factors and concurrent drug use.

Conclusions

Our study showed no significant associations between bisphosphonate exposure and female breast, cervical, and ovarian cancer. In the future, large prospective studies or a meta-analysis would be needed to verify the associations.
Appendix
Available only for authorised users
Literature
1.
Lewiecki EM (2010) Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis 1(3):115–128CrossRef
2.
Clézardin P, Ebetino FH, Fournier PG (2005) Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 65(12):4971–4974CrossRef
3.
Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M et al (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60(11):2949–2954PubMed
4.
Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12(20):6222s–6230sCrossRef
5.
Newcomb P, Trentham-Dietz A, Hampton J (2010) Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 102(5):799–802CrossRef
6.
Cardwell CR, Abnet CC, Veal P, Hughes CM, Cantwell MM, Murray LJ (2012) Exposure to oral bisphosphonates and risk of cancer. Int J Cancer 131(5):E717–E725CrossRef
7.
Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, Lane DS, Manson JAE, Snetselaar L, Yasmeen S, O’Sullivan MJ, Safford M, Hendrix SL, Wallace RB (2010) Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28(22):3582–3590CrossRef
8.
Vestergaard P, Fischer L, Mele M, Mosekilde L, Christiansen P (2011) Use of bisphosphonates and risk of breast cancer. Calcif Tissue Int 88(4):255–262CrossRef
9.
Ou YJ, Chiu HF, Wong YH, Yang CC, Yang YH (2017) Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 26(10):1286–1295CrossRef
10.
Monsees GM, Malone KE, Tang M-TC, Newcomb PA, Li CI (2011) Bisphosphonate use after estrogen receptor–positive breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst 103(23):1752–1760CrossRef
11.
Vinogradova Y, Coupland C, Hippisley-Cox J (2013) Exposure to bisphosphonates and risk of common non-gastrointestinal cancers: series of nested case–control studies using two primary-care databases. Br J Cancer 109(3):795–806CrossRef
12.
Rennert G, Pinchev M, Rennert HS (2010) Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28(22):3577–3581CrossRef
13.
Newcomb PA, Passarelli MN, Phipps AI, Anderson GL, Wactawski-Wende J, Ho GY et al (2015) Oral bisphosphonate use and risk of postmenopausal endometrial cancer. J Clin Oncol 33(10):1186–1190CrossRef
14.
Alford SH, Rattan R, Buekers TE, Munkarah AR (2015) Protective effect of bisphosphonates on endometrial cancer incidence in data from the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Cancer. 121(3):441–447CrossRef
15.
Rennert G, Rennert HS, Pinchev M, Lavie O (2014) The effect of bisphosphonates on the risk of endometrial and ovarian malignancies. Gynecol Oncol 133(2):309–313CrossRef
16.
Hue TF, Cummings SR, Cauley JA, Bauer DC, Ensrud KE, Barrett-Connor E, Black DM (2014) Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern Med 174(10):1550–1557CrossRef
17.
Chiang CH, Huang CC, Chan WL, Huang PH, Chen TJ, Chung CM, Lin SJ, Chen JW, Leu HB (2012) Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: a nationwide study. J Bone Miner Res 27(9):1951–1958CrossRef
18.
Lee W-Y, Sun L-M, Lin M-C, Liang J-A, Chang S-N, Sung F-C, Muo CH, Kao CH (2012) A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study. PLoS One 7(12):e53032CrossRef
19.
Torre LA, Siegel RL, Ward EM, Jemal A (2016) Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiology and Prevention Biomarkers 25(1):16–27CrossRef
20.
Shin J-Y, Park M-J, Lee SH, Choi S-H, Kim M-H, Choi N-K et al (2015) Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study. BMJ 351:h3517CrossRef
21.
World Health Organization (2006) The anatomical therapeutic chemical classification system with defined daily doses (ATC/DDD). WHO, Oslo
22.
Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, Saunders LD, Beck CA, Feasby TE, Ghali WA (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139CrossRef
23.
Who EC (2004) Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet (London, England) 363(9403):157CrossRef
24.
Park B, Sung J, Park K, Seo S, Kim S (2003) Report of the evaluation for validity of discharged diagnoses in Korean Health Insurance database. Seoul National University, Seoul, pp 19–52
25.
Clézardin P (2011) Bisphosphonates’ antitumor activity: an unravelled side of a multifaceted drug class. Bone. 48(1):71–79CrossRef
26.
Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285(7):885–892CrossRef
27.
Giraudo E, Inoue M, Hanahan D (2004) An amino-bisphosphonate targets MMP-9–expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114(5):623–633CrossRef
28.
Drake MT, Clarke BL, Khosla S (2008: Elsevier) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032–1045CrossRef
29.
Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD et al (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296(2):235–242PubMed
30.
Kim M-h, Chang J, Kim WJ, Banerjee S, Park SM (2018) Cumulative dose threshold for the chemopreventive effect of aspirin against gastric cancer. Am J Gastroenterol 113(6):845PubMed
Metadata
Title
Oral bisphosphonate use and the risk of female breast, ovarian, and cervical cancer: a nationwide population-based cohort study
Authors
Ye Seul Bae
Jooyoung Chang
Sang Min Park
Publication date
01-12-2019
Publisher
Springer London
Published in
Archives of Osteoporosis / Issue 1/2019
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-019-0588-z

Other articles of this Issue 1/2019

Archives of Osteoporosis 1/2019 Go to the issue

Original Article

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension

Short Communication

Low rate of densitometric diagnosis and treatment in patients with severe osteoporosis in Colombia

Original Article

The health and economic burden of osteoporotic fractures in Singapore and the potential impact of increasing treatment rates through more pharmacological options

Original Article

Dominant vs. non-dominant hip comparison in bone mineral density in young sporting athletes

Original Paper

Chinese patients’ preference for pharmaceutical treatments of osteoporosis: a discrete choice experiment

Original Article

Risk factors for conservative treatment failure in acute osteoporotic vertebral compression fractures (OVCFs)